NEXI Company Profile and Key Details
NexImmune, Inc.
NEXI Stock Price Chart
Stock Price Today
NexImmune, Inc. (NEXI) stock declined over -1.10%, trading at $0.10 on NASDAQ, down from the previous close of -. The stock opened at $0.10, fluctuating between $0.10 and $0.14 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Company Information
| Employees | 6 |
| Beta | 1.69 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
NexImmune, Inc. (NASDAQ: NEXI) stock price is $0.10 in the last trading session. During the trading session, NEXI stock reached the peak price of $0.14 while $0.10 was the lowest point it dropped to. The percentage change in NEXI stock occurred in the recent session was -1.1% while the dollar amount for the price change in NEXI stock was -$0.00.
The NASDAQ listed NEXI is part of Biotechnology industry that operates in the broader Healthcare sector. NexImmune, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Kristi Jones R.Ph.
Chief Executive Officer, Pres & Director
Mr. John Trainer M.B.A.
Chief Financial Officer
Dr. Jeffrey S. Weber M.D., Ph.D.
Chief Scientific Advisor, Co-Chairman of Scientific Advisory Board and Member of AI & ID SAB
Mr. Karen Haslbeck
Head of HR
Dr. Robert Douglas Knight M.D.
Chief Medical Officer
Dr. Daniel P. Bednarik
Senior Vice President of Molecular Engineering & Protein Design
Dr. Jerome Bernard Zeldis M.D., Ph.D.
Consultant
Dr. Jack A. Ragheb M.D., Ph.D.
Senior Vice President of Translational Science
Mr. Chad Rubin
Senior Vice President of Corporation Affairs
Dr. Mathias Oelke Ph.D.
Chief Scientific Officer
Mr. Matthew Schiller
Head of Bus. Devel.
NEXI's closing price is 41.41% higher than its 52-week low of $0.10 where as its distance from 52-week high of $28.70 is -99.51%.
Number of NEXI employees currently stands at 6.
Official Website of NEXI is: https://www.neximmune.com
NEXI could be contacted at phone 301 825 9810 and can also be accessed through its website. NEXI operates from 9119 Gaither Road, Gaithersburg, MD 20877, United States.
NEXI stock volume for the day was 116.3K shares. The average number of NEXI shares traded daily for last 3 months was 8.09K.
The market value of NEXI currently stands at $138.07K with its latest stock price at $0.10 and 1.39M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com